Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12622116 | 0.87 | ALDH1A1 (0.57) | MAPK1L3MBTL1KDM4EHTTMAPT | |
| SCHEMBL12625901 | 0.83 | POLB (0.56) | MAPK1L3MBTL1KDM4EHTTALDH1A1 | |
| SCHEMBL12655508 | 0.83 | HTT (0.62) | L3MBTL1KDM4EHTTMAPTNPC1 | |
| SCHEMBL12621891 | 0.83 | HTT (0.47) | KDM4EHTTMAPTNPC1ALDH1A1 | |
| SCHEMBL12621885 | 0.80 | HCRTR1 (0.53) | MAPK1L3MBTL1HTTMAPTNPC1 | |
| SCHEMBL25495300 | 0.77 | HTT (0.56) | L3MBTL1KDM4EHTTMAPTNPC1 | |
| SCHEMBL12626097 | 0.76 | KDM4E (0.61) | MAPK1KDM4EHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL15425990 | 0.75 | L3MBTL1 (0.67) | MAPK1L3MBTL1KDM4EHTTNPC1 | |
| SCHEMBL12622132 | 0.74 | L3MBTL1 (0.51) | MAPK1L3MBTL1KDM4EMAPTNPC1 | |
| SCHEMBL12622062 | 0.73 | L3MBTL1 (0.55) | L3MBTL1KDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661580-B2 | Method of inhibiting tau phosphorylation | CASSAVA SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-10017736-B2 | Method of inhibiting tau phosphorylation | PAIN THERAPEUTICS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-9500640-B2 | Alzheimer's disease assay in a living patient | PAIN THERAPEUTICS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9433604-B2 | Method for inhibiting growth of cancer cells | PAIN THERAPEUTICS INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-9354223-B2 | Alzheimer's disease assay in a living patient | PAIN THERAPEUTICS INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150148318-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | PAIN THERAPEUTICS, INC. | 2015-05-28 | — | — | US | disclosed |
| US-20140017698-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | WANG HOAU-YAN (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018341-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | CASSAVA SCIENCES, INC. | 2014-01-16 | — | — | US | disclosed |
| US-20140017699-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | CASSAVA SCIENCES, INC. | 2014-01-16 | — | — | US | disclosed |
| US-8580808-B2 | Filamin A-binding anti-inflammatory analgesic | Pain Therapeutic, Inc. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580809-B2 | Filamin A-binding anti-inflammatory analgesic | PAIN THERAPEUTICS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20110105484-A1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | PAIN THERAPEUTICS | 2011-05-05 | — | — | US | disclosed |
| US-20110105547-A1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | PAIN THERAPEUTICS | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105484-A1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | FLNA, FLNB, OPRK1 | MAPK1 2619/4885L3MBTL1 3970/4885KDM4E 2446/4885 |
| US-20110105547-A1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | FLNA, FLNB, OPRK1 | MAPK1 2619/4885L3MBTL1 3970/4885KDM4E 2446/4885 |
| US-20140018341-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | FLNA, FLNB, MAPT | MAPK1 45/4885L3MBTL1 1789/4885KDM4E 2906/4885 |
| US-11661580-B2 | Method of inhibiting tau phosphorylation | FLNA, FLNB, MAPT | MAPK1 45/4885L3MBTL1 1789/4885KDM4E 2906/4885 |
| US-10017736-B2 | Method of inhibiting tau phosphorylation | FLNA, FLNB, MAPT | MAPK1 45/4885L3MBTL1 1789/4885KDM4E 2906/4885 |
| US-20150148318-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | FLNA, FLNB, FSCN1 | MAPK1 10/4885L3MBTL1 1041/4885KDM4E 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.